Cinanserin is an inhibitor of the 3C-like proteinase of severe acute respiratory syndrome coronavirus and strongly reduces virus replication in vitro

Journal of Virology

Volumn 79, Issue 11, 2005, Pages 7095-7103

  Chen, Lili ^a   Gui, Chunshan ^a   Luo, Xiaomin ^a   Yang, Qingang ^a   Günther, Stephan ^b   Scandella, Elke ^c   Drosten, Christian ^b   Bai, Donglu ^a   He, Xichang ^a   Ludewig, Burkhard ^c   Chen, Jing ^a   Luo, Haibin ^a   Yang, Yiming ^a   Yang, Yifu ^a   Zou, Jianping ^a   Thiel, Volker ^c   Chen, Kaixian ^a   Shen, Jianhua ^a   Shen, Xu ^a   Jiang, Hualiang ^a,d  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b BERNHARD NOCHT INSTITUTE FOR TROPICAL MEDICINE   (Germany)

^c CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^d EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CINANSERIN; PROTEINASE; VIRUS RNA;

ANTIVIRAL ACTIVITY; ARTICLE; CATALYSIS; CONTROLLED STUDY; CORONAVIRUS; CRYSTALLOGRAPHY; DRUG BINDING; DRUG INHIBITION; NONHUMAN; PRIORITY JOURNAL; SEVERE ACUTE RESPIRATORY SYNDROME; SURFACE PLASMON RESONANCE; TISSUE CULTURE; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; BASE SEQUENCE; CELL LINE; CERCOPITHECUS AETHIOPS; CINANSERIN; CRICETINAE; CYSTEINE ENDOPEPTIDASES; DNA, VIRAL; DRUG EVALUATION, PRECLINICAL; ENDOPEPTIDASES; HUMANS; MODELS, MOLECULAR; PROTEASE INHIBITORS; RECOMBINANT PROTEINS; RNA REPLICASE; SARS VIRUS; USER-COMPUTER INTERFACE; VERO CELLS; VIRAL PROTEINS; VIRUS REPLICATION;

CORONAVIRUS; HUMAN CORONAVIRUS; HUMAN CORONAVIRUS 229E; SARS COV;

EID: 21044456863     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.79.11.7095-7103.2005     Document Type: Article

References (57)

1. Amundsen, B., and W. H. Lakey. 1970. The effect of 2′-(3- dimethylaminopropylthio) cinnamanilide on dog renal allograft survival. Surg. Forum 21:254-256.
2. Anand, K., J. Ziebuhr, P. Wadhwani, J. R. Mesters, and R. Hilgenfeld. 2003. Coronavirus main proteinase (3CLpro) structure: basis for design of anti- SARS drugs. Science 300:1763-1767.
3. Anonymous. 2004. Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003. World Health Organization, Geneva, Switzerland. [Online.] http://www.who.int/csr/sars/country/table2004_04_21/en/.
4. Boom, R., C. J. Sol, M. M. Salimans, C. L. Jansen, P. M. Wertheim-van Dillen, and J. van der Noordaa. 1990. Rapid and simple method for purification of nucleic acids. J. Clin. Microbiol. 28:495-503.
5. Clark, R. D., A. Strizhev, J. M. Leonard, J. F. Blake, and J. B. Matthew. 2002. Consensus scoring for ligand/protein interactions. J. Mol. Graph. Model. 20:281-295.
6. Cornell, W. D., P. Cieplak, C. I. Bayly, I. R. Gould, K. M. Merz, D. M. Ferguson, D. C. Spellmeyer, T. Fox, J. W. Caldwell, and P. A. Kollman. 1995. A second generation force field for the simulation of proteins, nucleic acids and organic molecules. J. Am. Chem. Soc. 117:5179-5197.
7. Davis, G. J., Q. M. Wang, G. A. Cox, R. B. Johnson, M. Wakulchik, C. A. Dotson, and E. C. Villarreal. 1997. Expression and purification of recombinant rhinovirus 14 3CD proteinase and its comparison to the 3C proteinase. Arch. Biochem. Biophys. 346:125-130.
8. Drosten, C., S. Gunther, W. Preiser, S. van der Werf, H. R. Brodt, S. Becker, H. Rabenau, M. Panning, L. Kolesnikova, R. A. Fouchier, A. Berger, A. M. Burguiere, J. Cinatl, M. Eickmann, N. Escriou, K. Grywna, S. Kramme, J. C. Manuguerra, S. Muller, V. Rickerts, M. Sturmer, S. Vieth, H. D. Klenk, A. D. Osterhaus, H. Schmitz, and H. W. Doerr. 2003. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N. Engl. J. Med. 348:1967-1976.
9. Egloff, M. P., F. Ferron, V. Campanacci, S. Longhi, C. Rancurel, H. Dutartre, E. J. Snijder, A. E. Gorbalenya, C. Cambillau, and B. Canard. 2004. The severe acute respiratory syndrome-coronavirus replicative protein nsp9 is a single-stranded RNA-binding subunit unique in the RNA virus world. Proc. Natl. Acad. Sci. USA 101:3792-3796.
10. Ewing, T. J. A., and I. D. Kuntz. 1997. Critical evaluation of search algorithms for automated molecular docking and database screening. J. Comput. Chem. 18:1175-1189.
11. Fouchier, R. A., N. G. Hartwig, T. M. Bestebroer, B. Niemeyer, J. C. de Jong, J. H. Simon, and A. D. Osterhaus. 2004. A previously undescribed coronavirus associated with respiratory disease in humans. Proc. Natl. Acad. Sci. USA 101:6212-6216.
12. Furgiuele, A. R., J. P. High, and Z. P. Horovitz. 1965. Some central effects of SQ 10,643 [2′3-(-dimethlaminopropylthio) cinnamanilide hydrochloride], a potent serotonin antagonist. Arch. Int. Pharmacodyn. Ther. 155:225-235.
13. Gallant, D. M., and M. P. Bishop. 1968. Cinanserin (SQ. 10,643): a preliminary evaluation in chronic schizophrenic patients. Curr. Ther. Res. Clin. Exp. 10:461-463.
14. Gao, F., H. Y. Ou, L. L. Chen, W. X. Zheng, and C. T. Zhang. 2003. Prediction of proteinase cleavage sites in polyproteins of coronaviruses and its applications in analyzing SARS-CoV genomes. FEBS Lett. 553:451-456.
15. Gasteiger, J., and M. Marsili. 1980. Iterative partial equalization of orbital electronegativity-a rapid access to atomic charges. Tetrahedron 36:3219-3228.
16. Günther, S., M. Asper, C. Röser, L. K. Luna, C. Drosten, B. Becker-Ziaja, P. Borowski, H.-M. Chen, and R. S. Hosmane. 2004, Application of real-time PCR for testing antiviral compounds against Lassa virus, SARS coronavirus and Ebola virus in vitro. Antiviral Res. 63:209-215.
17. Hertzig, T., E. Scandella, B. Schelle, J. Ziebuhr, S. G. Siddell, B. Ludewig, and V. Thiel. 2004. Rapid identification of coronavirus replicase inhibitors using a selectable replicon RNA. J. Gen. Virol. 85:1717-1725.
18. Holden, J. M., A. Keskiner, and P. Gannon. 1971. A clinical trial of an antiserotonin compound, cinanserin, in chronic schizophrenia. J. Clin. Pharmacol. New Drugs 11:220-226.
19. Hou, T., and X. Xu. 2004. Recent development and application of virtual screening in drug discovery: an overview. Curr. Pharm. Des. 10:1011-1033.
20. Itil, T. M., N. Polvan, and J. M. Holden. 1971. Clinical and electroencephalographic effects of cinanserin in schizophrenic and manic patients. Dis. Nerv. Syst. 32:193-200.
21. Ivanov, K. A., T. Hertzig, M. Rozanov, S. Bayer, V. Thiel, A. E. Gorbalenya, and J. Ziebuhr. 2004. Major genetic marker of nidoviruses encodes a replicative endoribonuclease. Proc. Natl. Acad. Sci. USA 101:12694-12699.
22. Ivanov, K. A., V. Thiel, J. C. Dobbe, Y. van der Meer, E. J. Snijder, and J. Ziebuhr. 2004. Multiple enzymatic activities associated with severe acute respiratory syndrome coronavirus helicase. J. Virol. 78:5619-5632.
23. Jenwitheesuk, E., and R. Samudrala. 2003. Identifying inhibitors of the SARS coronavirus proteinase. Bioorg. Med. Chem. Lett. 13:3989-3992.
24. Kane, F. J., Jr. 1970. Treatment of mania with cinanserin, an antiserotonin agent. Am. J. Psychiatry 126:1020-1023.
25. Ksiazek, T. G., D. Erdman, C. S. Goldsmith, S. R. Zaki, T. Peret, S. Emery, S. Tong, C. Urbani, J. A. Comer, W. Lim, P. E. Rollin, S. F. Dowell, A. E. Ling, C. D. Humphrey, W. J. Shieh, J. Guarner, C. D. Paddock, P. Rota, B. Fields, J. DeRisi, J. Y. Yang, N. Cox, J. M. Hughes, J. W. LeDuc, W. J. Bellini, and L. J. Anderson. 2003. A novel coronavirus associated with severe acute respiratory syndrome. N. Engl. J. Med. 348:1953-1966.
26. Kuo, C. J., Y. H. Chi, J. T. Hsu, and P. H. Liang. 2004. Characterization of SARS main protease and inhibitor assay using a fluorogenic substrate. Biochem. Biophys. Res. Commun. 318:862-867.
27. Lakey, W. H., and J. M. Leonard. 1970. Prolongation of skin homografts with 2′-(3-dimethylaminopropylthio) cinnamanilide. Surg. Forum 21:287-288.
28. Lee, N., D. Hui, A. Wu, P. Chan, P. Cameron, G. M. Joynt, A. Ahuja, M. Y. Yung, C. B. Leung, K. F. To, S. F. Lui, C. C. Szeto, S. Chung, and J. J. Sung. 2003. A major outbreak of severe acute respiratory syndrome in Hong Kong. N. Engl. J. Med. 348:1986-1994.
29. Maggiora, L. L., C. W. Smith, and Z. Y. Zhang. 1992. A general method for the preparation of internally quenched fluorogenic protease substrates using solid-phase peptide synthesis. J. Med. Chem. 35:3727-3730.
30. Marra, M. A., S. J. Jones, C. R. Astell, R. A. Holt, A. Brooks-Wilson, Y. S. Butterfield, J. Khattra, J. K. Asano, S. A. Barber, S. Y. Chan, A. Cloutier, S. M. Coughlin, D. Freeman, N. Girn, O. L. Griffith, S. R. Leach, M. Mayo, H. McDonald, S. B. Montgomery, P. K. Pandoh, A. S. Petrescu, A. G. Robertson, J. E. Schein, A. Siddiqui, D. E. Smailus, J. M. Stott, G. S. Yang, F. Plummer, A. Andonov, H. Artsob, N. Bastien, K. Bernard, T. F. Booth, D. Bowness, M. Czub, M. Drebot, L. Fernando, R. Flick, M. Garbutt, M. Gray, A. Grolla, S. Jones, H. Feldmann, A. Meyers, A. Kabani, Y. Li, S. Normand, U. Stroher, G. A. Tipples, S. Tyler, R. Vogrig, D. Ward, B. Watson, R. C. Brunham, M. Krajden, M. Petric, D. M. Skowronski, C. Upton, and R. L. Roper. 2003. The genome sequence of the SARS-associated coronavirus. Science 300:1399-1404.
31. Marsili, M., and J. Gasteiger. 1980. Pi-charge distributions from molecular topology and pi-orbital electronegativity. Croat. Chem. Acta 53:601-614.
32. Martina, B. E., B. L. Haagmans, T. Kuiken, R. A. Fouchier, G. F. Rimmelzwaan, G. Van Amerongen, J. S. Peiris, W. Lim, and A. D. Osterhaus. 2003. Virology: SARS virus infection of cats and ferrets. Nature 425:915.
33. Mengel, C. E., and C. A. Lotito. 1968. A new antiserotonin in the carcinoid syndrome. Arch. Intern. Med. 121:507-510.
34. Morris, G. M., D. S. Goodsell, R. S. Halliday, R. Huey, W. E. Hart, R. K. Belew, and A. J. Olson. 1998. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J. Comput. Chem. 19:1639-1662.
35. Murphy, G. P., H. D. Brede, H. W. Weber, J. H. Groenewald, and E. A. Mirand. 1970. The effect of cinanserin (antiserotonin agent) on canine renal allografts. J. Surg. Oncol. 2:145-154.
36. Peiris, J. S., S. T. Lai, L. L. Poon, Y. Guan, L. Y. Yam, W. Lim, J. Nicholls, W. K. Yee, W. W. Yan, M. T. Cheung, V. C. Cheng, K. H. Chan, D. N. Tsang, R. W. Yung, T. K. Ng, and K. Y. Yuen. 2003. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 361:1319-1325.
37. Poutanen, S. M., D. E. Low, B. Henry, S. Finkelstein, D. Rose, K. Green, R. Tellier, R. Draker, D. Adachi, M. Ayers, A. K. Chan, D. M. Skowronski, I. Salit, A. E. Simor, A. S. Slutsky, P. W. Doyle, M. Krajden, M. Petric, R. C. Brunham, and A. J. McGeer. 2003. Identification of severe acute respiratory syndrome in Canada. N. Engl. J. Med. 348:1995-2005.
38. Purcell, W. P., and J. A. Singer. 1967. Brief review and table of semiempirical parameters used in the Hückel molecular orbital method. J. Chem. Eng. Data 12:235-246.
39. Rota, P. A., M. S. Oberste, S. S. Monroe, W. A. Nix, R. Campagnoli, J. P. Icenogle, S. Penaranda, B. Bankamp, K. Maher, M. H. Chen, S. Tong, A. Tamin, L. Lowe, M. Frace, J. L. DeRisi, Q. Chen, D. Wang, D. D. Erdman, T. C. Peret, C. Burns, T. G. Ksiazek, P. E. Rollin, A. Sanchez, S. Liffick, B. Holloway, J. Limor, K. McCaustland, M. Olsen-Rasmussen, R. Fouchier, S. Gunther, A. D. Osterhaus, C. Drosten, M. A. Pallansch, L. J. Anderson, and W. J. Bellini. 2003. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 300:1394-1399.
40. Rubin, B., J. J. Piala, J. C. Burke, and B. N. Craver. 1964. A new, potent and specific serotonin inhibitor (Sq 10,643) 2′-(3- dimethylaminopropylthio) cinnamanilide hydrochloride: antiserotonin activity on uterus and on gastrointestinal, vascular, and respiratory systems of animals. Arch. Int. Pharmacodyn. Ther. 152:132-143.
41. Rubin, B., and M. H. Waugh. 1965. Antiphogistic effects of antiserotonin (Sq 10,643) and aminopyrine in rats versus endotoxin and other agents. Proc. Soc. Exp. Biol. Med 119:438-443.
42. Shoichet, B. K., S. L. McGovern, B. Wei, and J. J. Irwin. 2002. Lead discovery using molecular docking. Curr. Opin. Chem. Biol. 6:439-446.
43. Snijder, E. J., P. J. Bredenbeek, J. C. Dobbe, V. Thiel, J. Ziebuhr, L. L. Poon, Y. Guan, M. Rozanov, W. J. Spaan, and A. E. Gorbalenya. 2003. Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage. J. Mol. Biol. 331:991-1004.
44. Sun, H., H. Luo, C. Yu, T. Sun, J. Chen, S. Peng, J. Qin, J. Shen, Y. Yang, Y. Xie, K. Chen, Y. Wang, X. Shen, and H. Jiang. 2003. Molecular cloning, expression, purification, and mass spectrometric characterization of 3C-like protease of SARS coronavirus. Protein Expr. Purif. 32:302-308.
45. Sutton, G., E. Fry, L. Carter, S. Sainsbury, T. Walter, J. Nettleship, N. Berrow, R. Owens, R. Gilbert, A. Davidson, S. Siddell, L. L. Poon, J. Diprose, D. Alderton, M. Walsh, J. M. Grimes, and D. I. Stuart. 2004. The nsp9 replicase protein of SARS-coronavirus, structure and functional insights. Structure (Cambridge) 12:341-353.
46. ter Meulen, J., A. B. Bakker, E. N. van den Brink, G. J. Weverling, B. E. Martina, B. L. Haagmans, T. Kuiken, J. de Kruif, W. Preiser, W. Spaan, H. R. Gelderblom, J. Goudsmit, and A. D. Osterhaus. 2004. Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets. Lancet 363:2139-2141.
47. Thiel, V., K. A. Ivanov, A. Putics, T. Hertzig, B. Schelle, S. Bayer, B. Weissbrich, E. J. Snijder, H. Rabenau, H. W. Doerr, A. E. Gorbalenya, and J. Ziebuhr. 2003. Mechanisms and enzymes involved in SARS coronavirus genome expression. J. Gen. Virol. 84:2305-2315.
48. Traggiai, E., S. Becker, K. Subbarao, L. Kolesnikova, Y. Uematsu, M. R. Gismondo, B. R. Murphy, R. Rappuoli, and A. Lanzavecchia. 2004. An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat. Med. 10:871-875.
49. Tsang, K. W., P. L. Ho, G. C. Ooi, W. K. Yee, T. Wang, M. Chan-Yeung, W. K. Lam, W. H. Seto, L. Y. Yam, T. M. Cheung, P. C. Wong, B. Lam, M. S. Ip, J. Chan, K. Y. Yuen, and K. N. Lai. 2003. A cluster of cases of severe acute respiratory syndrome in Hong Kong. N. Engl. J. Med. 348:1977-1985.
50. van der Hoek, L., K. Pyrc, M. F. Jebbink, W. Vermeulen-Oost, R. J. Berkhout, K. C. Wolthers, P. M. Wertheim-van Dillen, J. Kaandorp, J. Spaargaren, and B. Berkhout. 2004. Identification of a new human coronavirus. Nat. Med. 10:368-373.
51. Wang, Q. M., R. B. Johnson, J. D. Cohen, G. T. Voy, J. M. Richardson, and L. N. Jungheim. 1997. Development of a continuous fluorescence assay for rhinovirus-14 3C protease using synthetic peptides. Antivir. Chem. Chemother. 8:303-310.
52. Woo, P. C., S. K. Lau, C. M. Chu, K. H. Chan, H. W. Tsoi, Y. Huang, B. H. Wong, R. W. Poon, J. J. Cai, W. K. Luk, L. L. Poon, S. S. Wong, Y. Guan, J. S. Peiris, and K. Y. Yuen. 2005. Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia. J. Virol. 79:884-895.
53. Wu, C. Y., J. T. Jan, S. H. Ma, C. J. Kuo, H. F. Juan, Y. S. Cheng, H. H. Hsu, H. C. Huang, D. Wu, A. Brik, F. S. Liang, R. S. Liu, J. M. Fang, S. T. Chen, P. H. Liang, and C. H. Wong. 2004. Small molecules targeting severe acute respiratory syndrome human coronavirus. Proc. Natl. Acad. Sci. USA 101:10012-10017.
54. Xiong, B., C. S. Gui, X. Y. Xu, C. Luo, J. Chen, H. B. Luo, L. L. Chen, G. W. Li, T. Sun, C. Y. Yu, L. D. Yue, W. H. Duan, J. K. Shen, L. Qin, T. L. Shi, Y. X. Li, K. X. Chen, X. M. Luo, X. Shen, J. H. Shen, and H. L. Jiang. 2003. A 3D model of SARS-CoV 3CL proteinase and its inhibitors design by virtual screening. Acta Pharmacol. Sin. 24:497-504.
55. Yang, H., M. Yang, Y. Ding, Y. Liu, Z. Lou, Z. Zhou, L. Sun, L. Mo, S. Ye, H. Pang, G. F. Gao, K. Anand, M. Bartlam, R. Hilgenfeld, and Z. Rao. 2003. The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor. Proc. Natl. Acad. Sci. USA 100:13190-13195.
56. Zhang, X. W., and Y. L. Yap. 2004. Exploring the binding mechanism of the main proteinase in SARS-associated coronavirus and its implication to anti- SARS drug design. Bioorg. Med. Chem. 12:2219-2223.
57. Ziebuhr, J., E. J. Snijder, and A. E. Gorbalenya. 2000. Virus-encoded proteinases and proteolytic processing in the Nidovirales. J. Gen. Virol. 81:853-879.